These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 33811778)

  • 1. AKT3 is a key regulator of head and neck squamous cell carcinoma.
    Takahashi H; Rokudai S; Kawabata-Iwakawa R; Sakakura K; Oyama T; Nishiyama M; Chikamatsu K
    Cancer Sci; 2021 Jun; 112(6):2325-2334. PubMed ID: 33811778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G-Protein-Coupled Receptor Kinase-Interacting Protein 1 (GIT1) Promotes Head and Neck Squamous Cell Carcinoma Metastases via Activating the PI3K/AKT/mTOR Signal Pathway.
    Xu R; Xu R; Wang Y; Wang W; Jiang L; Gong S
    Comput Math Methods Med; 2022; 2022():6881932. PubMed ID: 35116073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma.
    Chen X; Cao Y; Sedhom W; Lu L; Liu Y; Wang H; Oka M; Bornstein S; Said S; Song J; Lu SL
    Mol Oncol; 2020 Jan; 14(1):139-158. PubMed ID: 31600013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ITGA5 is associated with prognosis marker and immunosuppression in head and neck squamous cell carcinoma.
    Liu J; Wang Y; Chen X; Chen X; Zhang M
    Diagn Pathol; 2024 Oct; 19(1):134. PubMed ID: 39375732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis.
    Lee K; Chang JW; Oh C; Liu L; Jung SN; Won HR; Kim YI; Rha KS; Koo BS
    Eur J Surg Oncol; 2020 Jun; 46(6):1066-1073. PubMed ID: 31864826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma.
    Li B; Zhu J; Meng L
    Mol Med Rep; 2019 Feb; 19(2):877-884. PubMed ID: 30535476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.
    Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Fujita S
    Int J Oncol; 2019 Mar; 54(3):1021-1032. PubMed ID: 30569110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
    García-Escudero R; Segrelles C; Dueñas M; Pombo M; Ballestín C; Alonso-Riaño M; Nenclares P; Álvarez-Rodríguez R; Sánchez-Aniceto G; Ruíz-Alonso A; López-Cedrún JL; Paramio JM; Lorz C
    Oral Oncol; 2018 Apr; 79():55-63. PubMed ID: 29598951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant translation regulated by METTL1/WDR4-mediated tRNA N7-methylguanosine modification drives head and neck squamous cell carcinoma progression.
    Chen J; Li K; Chen J; Wang X; Ling R; Cheng M; Chen Z; Chen F; He Q; Li S; Zhang C; Jiang Y; Chen Q; Wang A; Chen D
    Cancer Commun (Lond); 2022 Mar; 42(3):223-244. PubMed ID: 35179319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P4HA2 contributes to head and neck squamous cell carcinoma progression and EMT through PI3K/AKT signaling pathway.
    Wu YL; Liu W; Zhao T; Jin J
    Med Oncol; 2024 May; 41(6):163. PubMed ID: 38777998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
    Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
    Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition.
    Ruicci KM; Plantinga P; Pinto N; Khan MI; Stecho W; Dhaliwal SS; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Nichols AC
    Mol Oncol; 2019 Oct; 13(10):2160-2177. PubMed ID: 31393061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
    Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
    IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CELSR3 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment.
    Wu Z; Zhu Z; Wu W; Hu S; Cao J; Huang X; Xie Q; Deng C
    Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3143-3156. PubMed ID: 38507078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profile of the PI3K-AKT-mTOR pathway in head and neck squamous cell carcinoma: Data from Brazilian population.
    Marques AEM; Borges GA; Viesi do Nascimento Filho CH; Vianna LMS; Ramos DDAR; Castilho RM; Squarize CH; Guerra ENS
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Apr; 133(4):453-461. PubMed ID: 35153184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
    Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
    Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.
    García-Carracedo D; Villaronga MÁ; Álvarez-Teijeiro S; Hermida-Prado F; Santamaría I; Allonca E; Suárez-Fernández L; Gonzalez MV; Balbín M; Astudillo A; Martínez-Camblor P; Su GH; Rodrigo JP; García-Pedrero JM
    Oncotarget; 2016 May; 7(20):29780-93. PubMed ID: 27119232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AKT3 Is a Novel Regulator of Cancer-Associated Fibroblasts in Head and Neck Squamous Cell Carcinoma.
    Takahashi H; Rokudai S; Kawabata-Iwakawa R; Sakakura K; Oyama T; Nishiyama M; Chikamatsu K
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p120-Catenin Downregulation and
    Kidacki M; Lehman HL; Green MV; Warrick JI; Stairs DB
    Mol Cancer Res; 2017 Oct; 15(10):1398-1409. PubMed ID: 28637905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.